

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A
AMENDMENT NO. 1

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2002

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 1-14131

ALKERMES, INC.

(Exact name of registrant as specified in its charter)

PENNSYLVANIA

23-2472830

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

88 Sidney Street, Cambridge, MA

02139-4136

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (617) 494-0171

64 Sidney Street, Cambridge, MA 02139-4136

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Shares Outstanding as of August 7, 2002
Common Stock, par value \$.01	64,312,182
Non-Voting Common Stock, par value \$.01	382,632

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. CONSOLIDATED FINANCIAL STATEMENTS:

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED STATEMENTS OF OPERATIONS

CONSOLIDATED STATEMENTS OF CASH FLOWS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Item 6. Exhibits and Reports on Form 8-K

SIGNATURES

CERTIFICATIONS

Exhibit Index

Ex-99.1 Certification of Chief Executive Officer

Ex-99.1 Certification of Chief Financial Officer

ALKERMES, INC. AND SUBSIDIARIES

INDEX

	Page No.
PART I — FINANCIAL INFORMATION	
Item 1. Consolidated Financial Statements	
Consolidated Balance Sheets - June 30, 2002 and March 31, 2002	3
Consolidated Statements of Operations - Three months ended June 30, 2002 and 2001	4
Consolidated Statements of Cash Flows - Three months ended June 30, 2002 and 2001	5
Notes to Consolidated Financial Statements	6
Item 6. Exhibits and Reports on Form 8-K	9
SIGNATURES	10
CERTIFICATIONS	10
EXHIBIT INDEX	11

Explanatory Note

The Registrant is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2002 to include summarized financial information with regard to a fifty percent or less owned person accounted for by the equity method by the Registrant in the notes to its financial statements. Accordingly, in this Form 10-Q/A, the Registrant is amending Note 4 to its Notes to Consolidated Financial Statements included in Item 1 to reflect such summarized financial information. This Form 10-Q/A does not reflect events occurring after the filing of the original Form 10-Q, or modify or update the disclosures therein in any way other than as required to reflect the amendment described above.

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements:

ALKERMES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (Unaudited)

	June 30, 2002	March 31, 2002
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 9,488,795	\$ 16,023,074
Short-term investments	100,338,942	136,323,768
Receivables from collaborative arrangements	19,501,908	19,039,706
Prepaid expenses and other current assets	5,647,655	5,249,797
Total current assets	134,977,300	176,636,345
Property, Plant and Equipment:		
Land	235,000	235,000
Building	5,076,961	5,058,936
Furniture, fixtures and equipment	51,274,335	49,558,745
Leasehold improvements	15,108,993	15,016,553
Construction in progress	41,245,053	26,497,064
	112,940,342	96,366,298
Less accumulated depreciation and amortization	(36,745,946)	(34,530,467)
	76,194,396	61,835,831
Investments	8,823,556	9,126,093
Investment in Reliant Pharmaceuticals, LLC	70,383,636	94,596,536
Other Assets	7,224,197	8,155,472
Total Assets	\$ 297,603,085	\$ 350,350,277
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable and accrued expenses	\$ 22,703,760	\$ 20,764,375
Accrued interest	2,881,226	1,013,521
Deferred revenue	6,807,177	7,083,516
Long-term obligations — current portion	3,900,000	14,025,000
Total current liabilities	36,292,163	42,886,412
Long-Term Obligations	6,825,000	7,800,000
Convertible Subordinated Notes	200,000,000	200,000,000
Shareholders' Equity:		
Capital stock, par value \$.01 per share: authorized, 4,550,000 shares; none issued		
Common stock, par value \$.01 per share:		
authorized, 160,000,000 shares; issued, 64,290,178 and 64,225,395 shares at June 30, 2002 and March 31, 2002, respectively	642,902	642,254
Non-voting common stock, par value \$.01 per share:		
authorized, 450,000 shares; issued, 382,632 at June 30, 2002 and March 31, 2002	3,826	3,826
Additional paid-in capital	444,851,926	444,425,742

Deferred compensation	(2,587,460)	(3,162,448)
Accumulated other comprehensive income	692,198	1,619,541
Accumulated deficit	(389,117,470)	(343,865,050)
	<u>54,485,922</u>	<u>99,663,865</u>
Total shareholders' equity		
	<u>54,485,922</u>	<u>99,663,865</u>
Total Liabilities and Shareholders' Equity	\$ 297,603,085	\$ 350,350,277
	<u>\$ 297,603,085</u>	<u>\$ 350,350,277</u>

See notes to consolidated financial statements.

ALKERMES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended June 30, 2002	Three Months Ended June 30, 2001
Revenues:		
Research and development revenue under collaborative arrangements	\$ 10,291,391	\$ 15,526,675
Expenses:		
Research and development	24,599,673	20,710,031
General and administrative	6,016,040	5,374,278
Total expenses	30,615,713	26,084,309
Net operating loss	(20,324,322)	(10,557,634)
Other income (expense):		
Interest income	1,365,936	4,525,015
Interest expense	(2,081,134)	(2,309,927)
Total other (expense) income	(715,198)	2,215,088
Equity in losses of Reliant Pharmaceuticals, LLC	24,212,900	—
Net loss	(\$45,252,420)	(\$8,342,546)
Basic and diluted loss per common share	(\$0.70)	(\$0.13)
Weighted average number of common shares outstanding	64,260,903	63,236,893

See notes to consolidated financial statements.

ALKERMES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended June 30, 2002	Three Months Ended June 30, 2001
Cash flows from operating activities:		
Net loss	(\$45,252,420)	(\$8,342,546)
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation, amortization and other noncash expenses	3,071,035	2,313,341
Equity in losses of Reliant Pharmaceuticals, LLC	24,212,900	—
Noncash interest expense	—	138,730
Adjustments to other assets	—	250,447
Changes in assets and liabilities:		
Receivables from collaborative arrangements	(462,201)	(6,132,254)
Prepaid expenses and other current assets	(400,779)	1,011,462
Accounts payable and accrued expenses	3,823,187	1,818,670
Deferred revenue	(276,341)	(579,472)
Net cash used by operating activities	<u>(15,284,619)</u>	<u>(9,521,622)</u>
Cash flows from investing activities:		
Additions to property, plant and equipment	(16,626,892)	(2,441,554)
Purchases of available-for-sale short-term investments	(35,290,276)	(69,221,396)
Sales of available-for-sale short-term investments	71,241,888	66,764,763
Purchases of held-to-maturity short-term investments, net	—	(19,309,847)
Maturities of long-term investments, net	—	38,739,459
Increase in other assets	—	(300,000)
Net cash provided by investing activities	<u>19,324,720</u>	<u>14,231,425</u>
Cash flows from financing activities:		
Proceeds from issuance of common stock	480,681	1,402,349
Repayment of loan	(10,000,000)	—
Payment of long-term obligations	(1,100,000)	(1,350,000)
Net cash (used by) provided by financing activities	<u>(10,619,319)</u>	<u>52,349</u>
Effect of exchange rate changes on cash	<u>44,939</u>	<u>(10,948)</u>
Net (decrease) increase in cash and cash equivalents	(6,534,279)	4,751,204
Cash and cash equivalents, beginning of period	<u>16,023,074</u>	<u>5,923,282</u>
Cash and cash equivalents, end of period	<u>\$ 9,488,795</u>	<u>\$ 10,674,486</u>
Supplementary information:		
Cash paid for interest	<u>\$ 213,428</u>	<u>\$ 301,123</u>

See notes to consolidated financial statements.

ALKERMES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

The consolidated financial statements of Alkermes, Inc. (the “Company”) for the three months ended June 30, 2002 and 2001 are unaudited and include all adjustments which are normal and recurring and, in the opinion of management, are necessary to present fairly the results of operations for the periods then ended. All such adjustments are of a normal recurring nature. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended March 31, 2002, which includes consolidated financial statements and notes thereto for the years ended March 31, 2002, 2001 and 2000. In addition, the financial statements include the accounts of Alkermes Controlled Therapeutics, Inc., Alkermes Controlled Therapeutics Inc. II, Advanced Inhalation Research, Inc. (“AIR”), Alkermes Investments, Inc., Alkermes Europe, Ltd. and Alkermes Development Corporation II (“ADC II”), wholly owned subsidiaries of the Company.

The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year.

The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America necessarily requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

2. COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes certain changes in the shareholders’ equity of the Company that are excluded from net income (loss). Specifically, other comprehensive income (loss) includes unrealized holding gains and losses on the Company’s “available-for-sale” securities and changes in cumulative foreign currency translation adjustments.

Comprehensive income (loss) for the three months ended June 30, 2002 and 2001 is as follows:

	Three Months Ended June 30, 2002	Three Months Ended June 30, 2001
Net loss	(\$45,252,420)	(\$8,342,546)
Foreign currency translation adjustments	49,908	(10,575)
Unrealized (loss) gain on marketable securities	(977,251)	9,182
Comprehensive loss	(\$46,179,763)	(\$8,343,939)

3. NET LOSS PER SHARE

Basic and diluted net loss per share are computed using the weighted average number of common shares outstanding during the period. Basic net loss per share excludes any dilutive effect from stock options and the 3 3/4% Convertible Subordinated Notes due 2007 (the “3 3/4% Notes”). The Company continues to be in a net loss position and, therefore, diluted net loss per share is the same amount as basic net loss per share. Certain securities were not included in the computations of diluted net loss per share for the three months ended June 30, 2002 and 2001 because they would have an antidilutive effect due to net losses for such periods. These securities include (i) outstanding stock options and awards with respect to 11,368,201 and 9,455,725 shares of common stock in the three months ended June 30, 2002 and 2001 and (ii) 2,952,030 shares of common stock issuable upon conversion of the 3 3/4% Notes in the three months ended June 30, 2002 and 2001.

4. INVESTMENT IN RELIANT PHARMACEUTICALS, LLC

In December 2001, the Company announced a strategic alliance with Reliant Pharmaceuticals, LLC, a privately held pharmaceutical company marketing branded, prescription pharmaceutical products to primary care physicians in the U.S.

As part of the alliance, in December 2001, the Company purchased approximately 63% of an offering by Reliant of its Series C Convertible Preferred Units, representing approximately 19% of the equity interest in Reliant, for a purchase price of \$100 million. The investment is being accounted for under the equity method of accounting because Reliant is organized as a limited liability company which is treated in a manner similar to a partnership. Because, at the time of the Company’s investment, Reliant had an accumulated deficit from operations and a deficit in members capital, under applicable accounting rules, the Company’s share of Reliant’s losses from the date of the investment will be recognized in proportion to the Company’s percentage participation in the Series C financing, and not in proportion to its percentage ownership interest in Reliant. The Company records its equity in the income or losses of Reliant three months in arrears. Reliant is a privately held company over which the Company does not exercise control and it relies on the unaudited financial statements prepared by Reliant and provided to the Company to calculate its share of Reliant’s losses in the Company’s consolidated statements of operations. The Company anticipates that Reliant will have substantial net losses through 2003, and accordingly, recorded its 63% share of such losses in its consolidated financial statements beginning in the quarter ended March 31, 2002.

Summarized financial information related to Reliant for the three-month period ended March 31, 2002 is as follows:

<u>(In thousands)</u>	
Revenues	\$ 58,609
Costs and expenses	88,461
Net loss	(29,644)

In connection with the Company’s \$100 million equity investment in Reliant, the Company is in the process of allocating its proportionate share of the assets acquired and liabilities assumed in accordance with the guidance set forth in Statement of Financial Accounting Standards (“SFAS”) No. 141. The Company took a \$2.7 million noncash charge for in-process research and development through the income statement under the caption “Equity in losses of Reliant Pharmaceuticals, LLC” in fiscal 2002. The \$2.7 million noncash charge is related to management’s current estimate of the amount of the purchase price to be allocated to in-process research and development. This analysis of the purchase price allocation is preliminary and the amount of in-process research and development is subject to future adjustment.

Termination of Proposed Merger Transaction with Reliant

On March 20, 2002, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Reliant. On August 14, 2002, the Company and Reliant announced the mutual termination of the Merger Agreement. The companies agreed to terminate due to general market conditions. There will be no payments triggered by the mutual termination and each company will bear its own legal and transaction fees.

5. RECENT ACCOUNTING PRONOUNCEMENTS

In August 2002, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” SFAS No. 146 addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring).” SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. The provisions of SFAS No. 146 are effective for exit or disposal activities that are initiated after December 31, 2002. The Company does not believe that the adoption of SFAS No. 146 will have a material impact on its financial statements and result of operations.

6. SUBSEQUENT EVENT

In August, the Company announced the regulatory approval and expected commercial launch of Risperdal Consta™ in Germany and the United Kingdom. Under the Company’s agreements with Janssen and based on the foregoing, certain minimum revenues are to be paid to the Company in minimum annual amounts for up to ten years beginning in calendar 2003. The actual amount of such minimum revenues will be determined by a formula and are currently estimated to aggregate approximately \$150 million. The minimum revenue obligation will be satisfied upon receipt by the Company of revenues equalling such aggregate amount of minimum revenues.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits:

Number	Exhibit
3.1	Third Amended and Restated Articles of Incorporation as filed with the Pennsylvania Secretary of State on June 7, 2001. (Incorporated by reference to Exhibit 3.1 to the Company's Report on Form 10-K for the fiscal year ended March 31, 2001).
3.2	Amended and Restated By-Laws of Alkermes, Inc., effective as of February 11, 2001. (Incorporated by reference to Exhibit 3.2 to the Company's Report on Form 10-K for the fiscal year ended March 31, 2001).
4.1	Specimen of Common Stock Certificate of Alkermes, Inc. (Incorporated by reference to Exhibit 4 to the Company's Registration Statement on Form S-1, as amended (File No. 33-40250)).
4.2	Specimen of Non-Voting Common Stock Certificate of Alkermes, Inc. (Incorporated by reference to Exhibit 4.4 to the Company's Report on Form 10-K for the fiscal year ended March 31, 1999).
4.3	Indenture, dated as of February 18, 2000, between Alkermes, Inc. and State Street Bank and Trust Company, as Trustee. (Incorporated by reference to Exhibit 4.6 to the Company's Registration Statement on Form S-3, as amended (File No. 333-31354)).
99.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 by Chief Executive Officer.
99.2	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 by Chief Financial Officer.

(b) During the quarter ended June 30, 2002, the Company filed a Current Report on Form 8-K, dated April 2, 2002, under Items 7 and 9 and a Current Report on Form 8-K, dated June 28, 2002, under Item 5.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused Amendment No. 1 to this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALKERMES, INC.
(Registrant)

Date: November 14, 2002

By: /s/ James M. Frates

James M. Frates
Vice President, Chief
Financial Officer and Treasurer
(Principal Financial and
Accounting Officer)

CERTIFICATIONS

I, Richard F. Pops, certify that:

1. I have reviewed this amendment no. 1 to the quarterly report on Form 10-Q/A of Alkermes, Inc.;
2. Based on my knowledge, this Amendment No. 1 to the quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Amendment No. 1 to the quarterly report; and
3. Based on my knowledge, the financial statements, and other financial information included in this Amendment No. 1 to the quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Amendment No. 1 to the quarterly report.

Date: November 14, 2002

/s/ Richard F. Pops

Richard F. Pops
Chief Executive Officer

CERTIFICATIONS

I, James M. Frates, certify that:

1. I have reviewed this amendment no. 1 to quarterly report on Form 10-Q/A of Alkermes, Inc.;
2. Based on my knowledge, this Amendment No. 1 to the quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Amendment No. 1 to the quarterly report; and
3. Based on my knowledge, the financial statements, and other financial information included in this Amendment No. 1 to the quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Amendment No. 1 to the quarterly report.

Date: November 14, 2002

/s/ James M. Frates

James M. Frates
Chief Financial Officer

Exhibit Index

Exhibit Number	Description
3.1	Third Amended and Restated Articles of Incorporation as filed with the Pennsylvania Secretary of State on June 7, 2001. (Incorporated by reference to Exhibit 3.1 to the Company's Report on Form 10-K for the fiscal year ended March 31, 2001).
3.2	Amended and Restated By-Laws of Alkermes, Inc., effective as of February 11, 2001. (Incorporated by reference to Exhibit 3.2 to the Company's Report on Form 10-K for the fiscal year ended March 31, 2001).
4.1	Specimen of Common Stock Certificate of Alkermes, Inc. (Incorporated by reference to Exhibit 4 to the Company's Registration Statement on Form S-1, as amended (File No. 33-40250)).
4.2	Specimen of Non-Voting Common Stock Certificate of Alkermes, Inc. (Incorporated by reference to Exhibit 4.4 to the Company's Report on Form 10-K for the fiscal year ended March 31, 1999).
5.3	Indenture, dated as of February 18, 2000, between Alkermes, Inc. and State Street Bank and Trust Company, as Trustee. (Incorporated by reference to Exhibit 4.6 to the Company's Registration Statement on Form S-3, as amended (File No. 333-31354)).
99.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 by Chief Executive Officer.
99.2	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 by Chief Financial Officer.